In the setting of anti-CD19 CAR T for CLL, pharmacologic inhibition of glycolysis, a pathway negatively associated with treatment response, improved CAR T proliferation and effector differentiation (15). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.